vildagliptin/metformin elvim 50 mg/1000 mg apvalkotās tabletes
elvim, sia, latvia - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
vildagliptin/metformin sanoswiss 50 mg/850 mg apvalkotās tabletes
sanoswiss uab, lithuania - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
vildagliptin/metformin sanoswiss 50 mg/1000 mg apvalkotās tabletes
sanoswiss uab, lithuania - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
augmentin fruit 400 mg/57 mg/5 ml pulveris iekšķīgi lietojamas suspensijas pagatavošanai
glaxosmithkline trading services limited, ireland - amoxicillinum, skābes clavulanicum - pulveris iekšķīgi lietojamas suspensijas pagatavošanai - 400 mg/57 mg/5 ml
augmentin 875 mg/125 mg apvalkotās tabletes
glaxosmithkline trading services limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg
augmentin 500 mg/125 mg apvalkotās tabletes
glaxosmithkline trading services limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 500 mg/125 mg
memantine lek
pharmathen s.a. - memantīna hidrohlorīds - alcheimera slimība - psychoanaleptics, , citas anti-demenci zāles - pacientiem ar vidēji smagu vai smagu alcheimera slimību ārstēšana.
nodetrip (previously xeristar)
esteve pharmaceuticals, s.a. - duloxetine - anxiety disorders; depressive disorder, major; diabetic neuropathies - psychoanaleptics, - attieksmi pret depresiju;Ārstēšana diabētiskās perifērās neiropātijas sāpju;Ārstēšana vispārēja trauksme;xeristar ir norādīts pieaugušie.
augmentin 1000 mg/200 mg pulveris injekciju/infūziju šķīduma pagatavošanai
glaxosmithkline trading services limited, ireland - amoxicillinum, skābes clavulanicum - pulveris injekciju/infūziju šķīduma pagatavošanai - 1000 mg/200 mg
iclusig
incyte biosciences distribution b.v. - ponatinibs - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. skatīt nodaļas 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.